China Collaborative Study on Epidemiology of Acute Kidney Injury

• Sponsor: XinLing Liang (Other)
• Overall Status: Unknown status
• CT.gov ID: NCT03054142
• Collaborator: (none)
• Enrollment: 1,000,000
• Location: 1
• Duration (Months): 60
• Patients Per Site Per Month: 16668.9

Study Details

Study Description

Brief Summary

Acute kidney injury (AKI) is a common clinical syndrome, especially patients in the hospital. AKI has become a huge medical burden in China. Little information is available about this disease burden in our country. The investigators aimed to evaluate the burden of AKI and to analyze the related risk factors.

Condition or Disease	Intervention/Treatment	Phase
Acute Kidney Injury	Other: no intervention

Detailed Description

The investigators launch a nationwide of all patients, who were admitted to hospital from 2011-2016. Patients were diagnosed on the basis of changes in serum creatinine by the laboratory information system. The investigators assessed rates of AKI according to the criteria of 2012 Kidney Disease Improving Global Outcomes (KDIGO).

Study Design

• Study Type: Observational
• Anticipated Enrollment: 1000000 participants
• Observational Model: Case-Control
• Time Perspective: Retrospective
• Official Title: China Collaborative Study on Epidemiology of Acute Kidney Injury
• Study Start Date: Jan 1, 2017
• Anticipated Primary Completion Date: Dec 1, 2021
• Anticipated Study Completion Date: Jan 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
AKI	Other: no intervention
non-AKI	Other: no intervention

Outcome Measures

Primary Outcome Measures

1. Incidence of AKI [Jan. 2011 to Oct. 2016]

Secondary Outcome Measures

1. Recognition rate of AKI [Jan. 2011 to Oct. 2016]

   Using machine learning and deep learning methods to establish AKI prediction model and risk models

2. Proportion of nephrology referral [Jan. 2011 to Oct. 2016]

3. In-hospital mortality [Jan. 2011 to Oct. 2016]

4. Longer ICU stay [Jan. 2011 to Oct. 2016]

5. Higher medical cost [Jan. 2011 to Oct. 2016]

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• The patients diagnosed on the basis of changes in serum creatinine according to the criteria of 2012 Kidney Disease Improving Global Outcomes(KDIGO)

Exclusion Criteria:

• Serum creatinine record less than two times during hospitalization

• Patients being diagnosed with End-stage kidney disease (chronic kidney disease stage

• Nephrectomy

• Kidney transplantation

• Peak serum creatinine of less than 53µ mol/L

• Serum creatinine decrease after amputation

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Nephrology Dept,Guangdong General Hospital	Guangzhou	Guangdong	China

Sponsors and Collaborators

• XinLing Liang

Investigators

• Principal Investigator: Liang Xinling, M.D.,Ph.D, Nephrology Dept,Guangdong General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: XinLing Liang, Director of Division of Nephrology and Blood Purification Center of Guangdong General Hospital, Guangdong Provincial People's Hospital
• ClinicalTrials.gov Identifier: NCT03054142
• Other Study ID Numbers: CCS-AKI RF2011-2016
• First Posted: Feb 15, 2017
• Last Update Posted: Jun 23, 2020
• Last Verified: Jun 1, 2020

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Additional relevant MeSH terms: Acute Kidney Injury; Wounds and Injuries

Study Results

No Results Posted as of Jun 23, 2020